Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04252430
Recruitment Status : Terminated (Due to other phase 3 trial failure to meet primary endpoint)
First Posted : February 5, 2020
Last Update Posted : May 13, 2020
Sponsor:
Collaborator:
Eurofins Optimed
Information provided by (Responsible Party):
MedDay Pharmaceuticals SA

Brief Summary:

This is a Phase 1, multicentric, open-label,two arms to assess and compare the effect of single oral administration of MD1003 on the pharmacokinetic parameters in renal impaired patients and healthy subjects with normal renal function.

The planned enrollment is 36 subjects (18 impaired patients and 18 healthy subjects).


Condition or disease Intervention/treatment Phase
Healthy Volunteers Impaired Renal Function Drug: MD1003 Phase 1

Detailed Description:

The study is a multicentric, open label, phase I, two arms study to compare pharmacokinetics of MD1003 after a single oral dose of MD1003 100 mg in 18 healthy male volunteers and in 18 renal impaired patients.

It is planned to enroll a total of 36 subjects to receive a single oral dose of investigational medicinal product (IMP):

  • 6 patients with mild renal impaired function, 6 patients with moderate renal impaired function and 6 patients with severe renal impaired function will be enrolled in four Hungarian centers;
  • 18 Healthy volunteers will be enrolled by Eurofins Optimed in Gières, France. Healthy volunteers will be matched with impaired renal function patients on ethnic group, sex, age and BMI.

Subjects will be screened for eligibility to participate in the study up to 21 days prior to the first administration. For both arms, subjects will be admitted into the Clinical Research Unit (CRU) on Day -3. On the morning of Day 1, subjects will receive a single 100 mg oral dose of MD1003 following an overnight fast (i.e., at least 10 hours). Subjects will be confined to the CRU until discharge on Day 8 with PK blood sample draws for measurement of MD1003 and its main metabolites being taken throughout the confinement (Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose). Urine sample draws for measurement of MD1003 and its main metabolites will also be taken throughout the study (pre-dose, ]D1T0h - D1T4h], ]D1T4h - D1T8h], ]D1T8h - D1T12h], ]D1T12h - D2T24h], ]D2T24h - D2T36h], ]D2T36h - D3T48h], ]D3T48h - D4T72h], ]D4T72h - D5T96h], ]D5T96h - D6T120h], ]D6T120h - D7T144h], ]D7T144h - D8T168h] post-dose). Then, subjects will come back to the CRU for 4 ambulatory visits on Day 10, Day 12, Day 14 and Day 16 for blood sampling (respectively 216, 264, 312, 360 hours post dose).

A follow-up post study visit will occur on Day 23 (±2 days) post-dose to ensure the ongoing wellbeing of the subjects.

Adverse events (AEs), clinical laboratory evaluations, vital signs assessments, 12-lead ECG and physical examination (PE) findings will be monitored at screening and at specified times during the study. All AEs will be recorded throughout the study (i.e., from signing of the Informed Consent Form until Study Completion).

The Study Completion is defined as the last subject's end-of-study assessment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Open label, Parallel-group, Single oral dose
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Other
Official Title: Open Label, Phase I Study to Assess and Compare the Pharmacokinetic Parameters After Single Oral Administration of MD1003 100 mg in Renal Impaired Patients and Healthy Subjects With Normal Renal Function
Actual Study Start Date : October 9, 2019
Actual Primary Completion Date : March 17, 2020
Actual Study Completion Date : March 17, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Tests

Arm Intervention/treatment
Active Comparator: Patients with renal impaired function
6 patients with mild renal impaired function, 6 patients with moderate renal impaired function and 6 patients with severe ranal impaired function
Drug: MD1003
Single oral dose administration of MD1003 at Day 1

Active Comparator: Healthy subjects
Healthy volunteers will be matched with impaired renal function patients
Drug: MD1003
Single oral dose administration of MD1003 at Day 1




Primary Outcome Measures :
  1. Area under curve from dosing time to last measurment (AUC (0-t)) for MD1003 [ Time Frame: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, 312 and 360 hours post-dose. ]
  2. Area under curve from dosing tme to infinity (AUC(0-∞)) for MD1003 [ Time Frame: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, 312 and 360 hours post-dose. ]
  3. Maximum plasma drug concentration (Cmax) for MD1003 [ Time Frame: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, 312 and 360 hours post-dose. ]
  4. Measurement of concentration of MD1003 [ Time Frame: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, 312 and 360 hours post-dose. ]
  5. Measurement of concentration of Bisnorbiotin [ Time Frame: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, 312 and 360 hours post-dose. ]
  6. Measurement of concentration of Biotin sulfoxide [ Time Frame: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, 312 and 360 hours post-dose. ]

Secondary Outcome Measures :
  1. Plasma pharmacokinetics: elimination half-life (t1/2) for MD1003 [ Time Frame: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, 312 and 360 hours post-dose. ]
  2. Plasma pharmacokinetics: elimination half-life (t1/2) for Bisnorbiotin [ Time Frame: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, 312 and 360 hours post-dose. ]
    Blood samples will be collected

  3. Plasma pharmacokinetics: elimination half-life (t1/2) for Biotin sulfoxide [ Time Frame: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, 312 and 360 hours post-dose. ]
    Blood samples will be collected

  4. Plasma pharmacokinetics: time for maximum plasma concentration (tmax) for MD1003 [ Time Frame: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, 312 and 360 hours post-dose. ]
    Blood samples will be collected

  5. Plasma pharmacokinetics: time for maximum plasma concentration (tmax) for Bisnorbiotin [ Time Frame: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, 312 and 360 hours post-dose. ]
    Blood samples will be collected

  6. Plasma pharmacokinetics: time for maximum plasma concentration (tmax) for Biotin sulfoxide [ Time Frame: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, 312 and 360 hours post-dose. ]
    Blood samples will be collected

  7. Plasma pharmacokinetics: elimination rate constant for MD1003 [ Time Frame: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, 312 and 360 hours post-dose. ]
    Blood samples will be collected

  8. Plasma pharmacokinetics: elimination rate constant for Bisnorbiotin [ Time Frame: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, 312 and 360 hours post-dose. ]
    Blood samples will be collected

  9. Plasma pharmacokinetics: elimination rate constant for Biotin sulfoxide [ Time Frame: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, 312 and 360 hours post-dose. ]
    Blood samples will be collected

  10. Plasma pharmacokinetics:: Apparent volume of distribution for MD1003 [ Time Frame: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, 312 and 360 hours post-dose. ]
    Blood samples will be collected

  11. Plasma pharmacokinetics:Aparrent clearance [ Time Frame: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, 312 and 360 hours post-dose. ]
    Blood samples will be collected

  12. Plasma pharmacokinetics: Percentage of extrapolated AUC inf for MD1003 [ Time Frame: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, 312 and 360 hours post-dose. ]
    Blood samples will be collected

  13. Plasma pharmacokinetics: Percentage of extrapolated AUC inf for Bisnorbiotin [ Time Frame: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, 312 and 360 hours post-dose. ]
    Blood samples will be collected

  14. Plasma pharmacokinetics: Percentage of extrapolated AUC inf for Biotin sulfoxide [ Time Frame: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, 312 and 360 hours post-dose. ]
    Blood samples will be collected

  15. Area under curve from dosing tme to infinity (AUC(0-∞)) for Bisnorbiotin [ Time Frame: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, 312 and 360 hours post-dose. ]
    Blood samples will be collected for the measurement of concentration for Bisnorbiotin

  16. Area under curve from dosing tme to infinity (AUC(0-∞)) for Biotin sulfoxide [ Time Frame: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, 312 and 360 hours post-dose. ]
    Blood samples will be collected for the measurement of concentration for Biotin sulfoxide

  17. Area under curve from dosing time to last measurement (AUC (0-t)) for Bisnorbiotin [ Time Frame: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, 312 and 360 hours post-dose. ]
    Blood samples will be collected for the measurement of concentration for Bisnorbiotin

  18. Area under curve from dosing time to last measurement (AUC (0-t)) for Biotin sulfoxide [ Time Frame: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, 312 and 360 hours post-dose. ]
    Blood samples will be collected for the measurement of concentration for Biotin sulfoxide

  19. Maximum plasma drug concentration (Cmax) for Bisnorbiotin [ Time Frame: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, 312 and 360 hours post-dose. ]
    Blood samples will be collected for the measurement for concentration for Bisnorbiotin

  20. Maximum plasma drug concentration (Cmax) for Biotin sulfoxide [ Time Frame: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, 312 and 360 hours post-dose. ]
    Blood samples will be collected for the measurement of concentration for Biotin sulfoxide

  21. Total amount excreted MD1003, Bisnorbiotin and Biotin sulfoxide urine over the time interval between t1 and t2 (Ae t1-t2) [ Time Frame: predose to 168 hours post-dose ]
  22. Total amount excreted MD1003, Bisnorbiotin and Biotin sulfoxide urine over the total time interval of urine collection (Ae0-t) [ Time Frame: up to 168 hours post-dose ]
  23. Renal calculated clairance [ Time Frame: predose to 168 hours post-dose. ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

For eligibility into the trial, subjects and patients must meet all the following inclusion criteria:

  1. Male or female subjects, aged 18 to 75 years inclusive
  2. Females participating in this study must be of non-childbearing potential or using highly effective contraception for the full duration of the study and for 1 month after the end of treatment, as described below:

    • Cessation of menses for at least 12 months due to ovarian failure;
    • Surgical sterilization such as bilateral oophorectomy, hysterectomy, or medically documented ovarian failure;
    • Using an highly effective non-hormonal method of contraception (bilateral tubal occlusion, vasectomized partner or intra-uterine device);
    • Double contraception with barrier AND highly effective hormonal method of contraception (oral, intravaginal or transdermal combined estrogen and progestogen hormonal contraception associated with inhibition of ovulation, oral, injectable or implantable progestogen-only hormonal contraception associated with inhibition of ovulation or intrauterine hormone-releasing system). The hormonal contraception must be started at least one month prior to inclusion.
  3. Negative serum pregnancy test at screening (if applicable);
  4. Normal hepatic function;
  5. Non-smoker subject or smoker of not more than 5 cigarettes a day;
  6. Signing a written informed consent prior to selection;
  7. Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research.

For renal impaired patients:

  1. Renal impairment patients with mild decrease in estimated creatinine clearance (CLcr) (60 ≤ CLcr ≤ 89 mL.min) or with moderate decrease of CLcr (30 ≤ CLcr ≤ 59 mL.min) or severe decrease of CLcr (15 ≤ CLcr ≤ 29 mL.min) using the Cockcroft-Gault equation;
  2. Supine blood pressure ≤ 170/110 mmHg;
  3. Documented renal impairment indicated by reduced estimated creatinine clearance within 12 months of screening or longer;
  4. Stable renal function as evidenced by ≤ 30% difference in two evaluation of estimated creatinine clearance on two separate occasions separated by at least 28 days with one measurement being the value at screening;
  5. Body Mass Index (BMI) between 20 and 34 kg/m2 inclusive.

For healthy subjects with normal renal function:

  1. Considered as healthy after a comprehensive clinical assessment (detailed medical history and complete physical examination);
  2. Estimated creatinine clearance (CLcr) ≥ 90 mL/min;
  3. No proteinuria (< 0.15 g/L determined by urinalysis);
  4. Body Mass Index (BMI) between 20 and 30 kg/m2 inclusive and body weight (BW) not lower than 55 kg;
  5. Normal Blood Pressure (BP) and Heart Rate (HR) at the screening visit after 10 minutes in supine position:

    • 90 mmHg ≤ Systolic Blood Pressure (SBP) ≤ 145 mmHg,
    • 50 mmHg ≤ Diastolic Blood Pressure (DBP) ≤ 90 mmHg,
    • 45 bpm ≤ HR ≤ 90 bpm,
    • Or considered NCs by investigators;
  6. Normal ECG recording on a 12-lead ECG at the screening visit:

    • 120 < PR < 220 ms,
    • QRS < 110 ms,
    • QTcf ≤ 430 ms for male and < 450 ms for female,
    • No sign of any trouble of sinusal automatism,
    • Or considered NCs by investigators;
  7. Laboratory parameters within the normal range of the laboratory (hematological, blood chemistry tests, urinalysis). Individual values out of the normal range can be accepted if judged clinically non relevant by the Investigator;
  8. Normal dietary habits;
  9. Matched to at least 1 renal impaired patient by ethnic group, sex, age (+/- 10 years) and BMI (+/- 20%).

Exclusion Criteria:

  1. Positive Hepatitis B surface (HBs) antigen or anti Hepatitis C Virus (HCV) antibody, or positive results for Human Immunodeficiency Virus (HIV) 1 or 2 tests);
  2. History or presence of drug or alcohol abuse (alcohol consumption > 40 grams/day);
  3. Subject/Patient who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development;
  4. Subject/Patient who cannot be contacted in case of emergency;
  5. History or presence of allergy or unusual reactions to some drugs or anesthetics or known hypersensitivity to the investigation product or its excipients (including lactose intolerance);
  6. Any medications intake within 3 months that may interfere with absorption, distribution, metabolism or excretion of the study drug, or any medication that may result in induction or inhibition of microsomal enzymes;
  7. Subject/Patient who is in the exclusion period of a previous study;
  8. Administrative or legal supervision;
  9. Blood donation (including in the frame of a clinical trial) within 2 months before administration or blood donation planned during the study or within 2 months following participation to the study;
  10. Subject/Patient who is pregnant or breastfeeding. Subject/Patient should not be enrolled if she plans to become pregnant during the time of study participation;
  11. Excessive consumption of beverages with xanthine bases (> 4 cups or glasses / day);
  12. Positive results of screening for drugs of abuse;
  13. Intake of any food or any beverage containing grapefruit or grapefruit juice within 48h prior to the first dosing and the inability to stop such intake during the study;
  14. Evidence or history of clinically significant uncontrolled hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, metabolic, systemic, infectious, or allergic disease (including drug hypersensitivity or allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing);
  15. General anesthesia within 3 months before administration;
  16. Major surgery within 28 days prior to inclusion or major surgery planned during the next 6 months.

For renal impaired patients:

  1. History of renal transplant;
  2. The patient has evidence of an unstable clinically important medical condition other than impaired renal function;
  3. The patient has an acute exacerbation or unstable renal function, as indicated by worsening of clinical and/or laboratory signs of renal impairment, within the 4 weeks before study drug administration;
  4. Patients undergoing any method of dialysis or hemofiltration;
  5. Disorders or surgery of the gastrointestinal tract which may interfere with drug absorption or may otherwise influence the pharmacokinetics of the investigational medicinal product (e.g., inflammatory bowel disease, resections of the small or large intestine, etc.);
  6. History of febrile illness within 5 days prior to dosing;
  7. Evidence of clinically significant liver disease or liver damage (e.g., hepatitis B or C, autoimmune hepatitis, primary biliary cirrhosis, non-alcoholic fatty liver disease, elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) that is considered clinically significant by the Investigator, etc.). Presence or history of protein drug hypersensitivity, or allergic disease diagnosed and treated by a physician;
  8. Any drug intake during the 2 weeks or 5 half-lives of the drug preceding the first administration.

For Healthy subjects with normal renal function:

  1. Any history or presence of renal disease
  2. Frequent headaches (> twice a month) and / or migraines, recurrent nausea and / or vomiting;
  3. Symptomatic hypotension whatever the decrease of blood pressure or asymptomatic postural hypotension defined by a decrease in SBP (≥20 mmHg) or DBP (≥20 mmHg) within two minutes when changing from the supine to the standing position;
  4. Inability to abstain from intensive muscular effort;
  5. Any drug intake (except paracetamol 3g/d or contraception) during the 2 weeks or 5 half-lives of the drug preceding the first administration;
  6. Subject who would receive more than 4500 euros as indemnities for his participation in biomedical research within the 12 last months, including the indemnities for the present study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04252430


Locations
Layout table for location information
France
Eurofins Optimed
Gières, France, 38610
Hungary
DRC Drug Research Center Ltd.
Balatonfüred, Hungary, 8231
Semmelweis University Faculty of Medicine
Budapest, Hungary, 1083
University of Debrecen Medical and Health Center
Debrecen, Hungary, 4032
Clinical Research Units Hungary Ltd.
Miskolc, Hungary, 3528
Sponsors and Collaborators
MedDay Pharmaceuticals SA
Eurofins Optimed
Investigators
Layout table for investigator information
Principal Investigator: Yves Donazzolo, MD Eurofins Optimed
Layout table for additonal information
Responsible Party: MedDay Pharmaceuticals SA
ClinicalTrials.gov Identifier: NCT04252430    
Other Study ID Numbers: MD1003CT2019602RI
2019-002315-26 ( EudraCT Number )
First Posted: February 5, 2020    Key Record Dates
Last Update Posted: May 13, 2020
Last Verified: October 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Renal Insufficiency
Kidney Diseases
Urologic Diseases